12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

GLPG1205: Phase I started

Galapagos began a double-blind, placebo-controlled, Belgian Phase I trial to evaluate ascending doses of oral GLPG1205 in about 40 healthy men. Subjects will receive single doses of 10-800 mg GLPG1205 and 100-400 mg GLPG1205 daily for 14 days....

Read the full 167 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >